Algernon Pharmaceuticals Inc., of Vancouver, British Columbia, said the exercise date of 4 million warrants originally set to expire on July 18, 2020, was extended to July 18, 2021, with no change in exercise price.

Allovir Inc., of Cambridge, Mass., filed with the SEC for an IPO of up to $100 million, including potential overallotments, to fund expenses for planned phase II and III trials of lead candidate, Viralym-M, a multivirus-specific T-cell therapy targeting five viruses. The company is focusing initially on treating immunocompromised allogeneic hematopoietic stem cell transplant and solid organ transplant patients at high risk for life-threatening viral infections from the viruses targeted by Viralym-M. The Baylor College of Medicine spin-out previously reported positive data from a completed phase II trial. The company said IPO proceeds also will fund planned trials of pipeline candidates ALVR-106, a virus-specific T-cell therapy targeting respiratory viruses, and allogeneic virus-targeted cell therapies ALVR-107 in chronic human hepatitis B virus, ALVR-108 in human herpes virus 8-associated diseases and ALVR-109 in COVID-19 infection. Allovir, which in 2019 raised a $120 million series B, plans to list on Nasdaq under the symbol ALVR. Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, SVB Leerink LLC and Piper Sandler and Co. are joint bookrunners on the deal, which was not priced.

Ascendis Pharma A/S, of Copenhagen, said it plans to offer $500 million of American depositary shares (ADSs) in an underwritten public offering and to grant underwriters a 30-day option to purchase up to $75 million in additional ADSs. J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group LLC and SVB Leerink are joint book-running managers for the offering, which was not priced. On July 7, the company’s ADSs (NASDAQ:ASND) fell $4.28 to close at $147.60.

Evolus Inc., of Newport Beach, Calif., said its partner, Daewoong Pharmaceutical Co. Ltd., of Seoul, Korea, plans to invest $40 million in a five-year, unsecured, subordinated, 3% convertible note at a conversion price of $13, representing a 144% premium to the $5.32 closing price of Evolus shares (NASDAQ:EOLS) on July 6. The investment is expected to be funded prior to July 31. On July 7, the company’s shares fell more than 27%, closing at $3.83 for a loss of $1.46, following a nonbinding notice of initial determination by the U.S. International Trade Commission, which Evolus said would not affect the launch of its Jeuveau (prabotulinumtoxinA-xvfs) aesthetic neurotoxin.

Inventiva SA, of Daix, France, set terms for its U.S. IPO, disclosing plans to raise $102 million by offering 7.5 million American depositary shares at $13.68 apiece, the as-converted close of its shares on July 3, on the Euronext Paris, where the company trades as IVA. Inventiva plans to list on Nasdaq under the ticker IVA. Jefferies LLC, Stifel Nicolaus & Co. Inc., Guggenheim Securities LLC and H.C. Wainwright and Co. are joint bookrunners.

Molecular Partners AG, of Zurich-Schlieren, Switzerland, said it placed approximately 5.5 million registered shares, corresponding to approximately 25% of the company’s registered share capital, through an accelerated bookbuilding process at an offering price of CHF14.50 (US$15.40) apiece for gross proceeds of approximately CHF80.2 million. The offering included participation by new and existing institutional investors, including Suvretta Capital Management LLC, Camber Capital Management LP, BVF Partners LP, Federated Hermes Kaufmann Funds and Monashee Investment Management LLC. The new shares will be issued from the company’s authorized share capital under exclusion of existing shareholders’ pre-emptive rights and are expected to be listed on the SIX Swiss Exchange, where the company trades as MOLN, on July 9. SVB Leerink LLC, Cowen and Co. LLC, Credit Suisse AG and Van Lanschot Kempen Wealth Management NV acted as joint bookrunners, with H.C. Wainwright & Co. and Octavian AG as financial advisors.

Oryzon Genomics SA, of Madrid, Spain, said it raised approximately €20 million (US$22.6 million) through a private placement of approximately 7.3 million common shares priced at €2.75 apiece, representing a 10.7% discount from the June 24, closing price of €3.08 for the company’s shares, which trade on the Madrid Stock Exchange as ORY. The company said proceeds will extend its runway into the first quarter of 2023, supporting its precision medicine approach to treat genetically defined subpopulations of psychiatric patients and enabling it to prepare the phase II Alice-2 trial of LSD-1 inhibitor iadademstat dihydrochloride in acute myeloid leukemia. The new shares were admitted to trading on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges through the Spanish Automated Quotation System on June 28. On July 7, ORY shares closed on the MSE at €3.17.

Pear Therapeutics Inc., of Boston, said it closed a credit facility for up to $50 million from Perceptive Advisors, in return issuing warrants to Perceptive. The company said proceeds will be used, in part, for commercialization activities for its three FDA-authorized prescription digital therapeutics.

Poseida Therapeutics Inc., of San Diego, set terms for its IPO, proposing to raise $150 million by offering 10 million shares priced in a range of $14 to $16 to fund ongoing development of its pipeline, including lead candidate P-BCMA-101, an autologous CAR T that’s in a potentially registrational phase II trial to treat multiple myeloma. Poseida, which plans to list on Nasdaq as PSTX, raised $110 million in June 2020 in a series D financing that came on the heels of its IPO filing. Bofa Securities, Piper Sandler and William Blair are joint bookrunners on the deal.

Revolution Medicines Inc., of Redwood City, Calif., said it is offering 5.5 million common shares in an underwritten public offering and plans to grant underwriters a 30-day option to purchase up to 825,000 additional shares. Proceeds will fund development of multiple RAS programs, including its active GTP-bound form of RAS and its son of sevenless homolog 1 inhibitor program, as well as its 4EBP1/mTORC1 inhibitor program, all targeting the treatment of cancer. J.P. Morgan Securities LLC, Cowen and Co. LLC, SVB Leerink LLC and Guggenheim Securities LLC are joint book-running managers for the offering, which was not priced. On July 7, the company’s shares (NASDAQ:RVMD) dropped $3.38 to close at $26.08.

Tenax Therapeutics Inc., of Morrisville, N.C., said it inked a definitive agreement with a single health care-focused institutional investor for a registered direct offering of about 2.5 million common shares priced at-the-market at $1.02780 apiece along with prefunded warrants to purchase up to 652,313 additional shares at $1.02770 apiece. Tenax also agreed to issue the investor prefunded warrants to purchase up to approximately 4.6 million common shares at the registered direct offering price in a concurrent private placement as well as unregistered warrants to purchase up to approximately 7.8 million shares. The company expects the offerings to raise approximately $8 million, with net proceeds expected primarily to fund trials of potassium channel stimulator levosimendan. H.C. Wainwright & Co. is exclusive placement agent for the offerings, which are expected to close by July 8. The company’s shares (NASDAQ:TENX) gained 3 cents on July 7 to close at 95 cents.

Vor Biopharma LLC, of Cambridge, Mass., said it raised $110 million in a series B financing to advance its lead candidate, CD33 modulator VOR-33, into clinical trials and to accelerate validation of additional targets for its scientific platform, designed to remove redundant proteins so that transplanted stem cells become invisible to targeted therapies while leaving diseased cells vulnerable. Vor is targeting treatment of acute myeloid leukemia and other hematologic malignancies. RA Capital Management led the financing, which included new investors Fidelity Management & Research Co. LLC, Pagliuca Family Office, Alexandria Venture Investments and undisclosed investors, including additional institutional crossover investors. Existing investors 5AM Ventures, Johnson & Johnson Innovation-JJDC Inc., Osage University Partners and co-founder Puretech Health also participated in the round.

No Comments